Topics

Poxel Announces Favorable Results for PXL065 Phase 1a Single Ascending Dose Trial

12:01 EDT 8 Apr 2019 | FinanzNachrichten

PXL065 observed to have a favorable safety, tolerability and pharmacokinetic profile in the Phase 1a trial PXL065 is advancing into a Phase 1b multiple ascending dose trial to support a pivotal Ph...

Original Article: Poxel Announces Favorable Results for PXL065 Phase 1a Single Ascending Dose Trial

NEXT ARTICLE

More From BioPortfolio on "Poxel Announces Favorable Results for PXL065 Phase 1a Single Ascending Dose Trial"

Quick Search